Braveheart Bio, Inc. (NASDAQ:BRVE – Get Free Report) Director Erez Chimovits acquired 1,940,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $34,920,000.00. Following the acquisition, the director owned 11,901,826 shares in the company, valued at approximately $214,232,868. The trade was a 19.47% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ BRVE opened at $25.01 on Wednesday. Braveheart Bio, Inc. has a 1-year low of $24.61 and a 1-year high of $32.00.

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

• Five stocks we like better than Braveheart Bio
• Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
• AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
• NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
• Apple’s Next iPhone Could Test How Much Pricing Power Is Left

Receive News & Ratings for Braveheart Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Braveheart Bio and related companies with MarketBeat.com's FREE daily email newsletter.